Logo image of BGBIO.OL

BERGENBIO ASA (BGBIO.OL) Stock Fundamental Analysis

Europe - OSL:BGBIO - NO0013251173 - Common Stock

1.198 NOK
+0.07 (+5.83%)
Last: 10/30/2025, 3:44:05 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BGBIO. BGBIO was compared to 75 industry peers in the Biotechnology industry. The financial health of BGBIO is average, but there are quite some concerns on its profitability. BGBIO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BGBIO has reported negative net income.
In the past year BGBIO has reported a negative cash flow from operations.
In the past 5 years BGBIO always reported negative net income.
BGBIO had a negative operating cash flow in each of the past 5 years.
BGBIO.OL Yearly Net Income VS EBIT VS OCF VS FCFBGBIO.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -160.55%, BGBIO is doing worse than 86.84% of the companies in the same industry.
Looking at the Return On Equity, with a value of -207.87%, BGBIO is doing worse than 61.84% of the companies in the same industry.
Industry RankSector Rank
ROA -160.55%
ROE -207.87%
ROIC N/A
ROA(3y)-126.61%
ROA(5y)-96.68%
ROE(3y)-201.42%
ROE(5y)-144.62%
ROIC(3y)N/A
ROIC(5y)N/A
BGBIO.OL Yearly ROA, ROE, ROICBGBIO.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BGBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BGBIO.OL Yearly Profit, Operating, Gross MarginsBGBIO.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

BGBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BGBIO has been increased compared to 1 year ago.
The number of shares outstanding for BGBIO has been reduced compared to 5 years ago.
BGBIO has a worse debt/assets ratio than last year.
BGBIO.OL Yearly Shares OutstandingBGBIO.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
BGBIO.OL Yearly Total Debt VS Total AssetsBGBIO.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -3.91, we must say that BGBIO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BGBIO (-3.91) is worse than 67.11% of its industry peers.
There is no outstanding debt for BGBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.91
ROIC/WACCN/A
WACC8.49%
BGBIO.OL Yearly LT Debt VS Equity VS FCFBGBIO.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 4.39 indicates that BGBIO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.39, BGBIO is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
A Quick Ratio of 4.39 indicates that BGBIO has no problem at all paying its short term obligations.
BGBIO has a better Quick ratio (4.39) than 76.32% of its industry peers.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.39
BGBIO.OL Yearly Current Assets VS Current LiabilitesBGBIO.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.32% over the past year.
Looking at the last year, BGBIO shows a very strong growth in Revenue. The Revenue has grown by 139.55%.
Measured over the past years, BGBIO shows a very negative growth in Revenue. The Revenue has been decreasing by -37.51% on average per year.
EPS 1Y (TTM)70.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.07%
Revenue 1Y (TTM)139.55%
Revenue growth 3Y3.09%
Revenue growth 5Y-37.51%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BGBIO will show a very negative growth in Earnings Per Share. The EPS will decrease by -15.45% on average per year.
Based on estimates for the next years, BGBIO will show a very strong growth in Revenue. The Revenue will grow by 210.58% on average per year.
EPS Next Y17.6%
EPS Next 2Y-31.23%
EPS Next 3Y-17.38%
EPS Next 5Y-15.45%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y210.58%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BGBIO.OL Yearly Revenue VS EstimatesBGBIO.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2028 50M 100M 150M 200M 250M
BGBIO.OL Yearly EPS VS EstimatesBGBIO.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BGBIO. In the last year negative earnings were reported.
Also next year BGBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGBIO.OL Price Earnings VS Forward Price EarningsBGBIO.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGBIO.OL Per share dataBGBIO.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

BGBIO's earnings are expected to decrease with -17.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.23%
EPS Next 3Y-17.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BGBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BERGENBIO ASA

OSL:BGBIO (10/30/2025, 3:44:05 PM)

1.198

+0.07 (+5.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-20 2025-08-20
Earnings (Next)11-11 2025-11-11
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap46.83M
Revenue(TTM)848.00K
Net Income(TTM)-139.28M
Analysts40
Price Target5.1 (325.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 55.22
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.7
EV/EBITDA N/A
EPS(TTM)-3.75
EYN/A
EPS(NY)-6.46
Fwd EYN/A
FCF(TTM)-3.53
FCFYN/A
OCF(TTM)-3.53
OCFYN/A
SpS0.02
BVpS1.71
TBVpS1.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -160.55%
ROE -207.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-126.61%
ROA(5y)-96.68%
ROE(3y)-201.42%
ROE(5y)-144.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.39
Altman-Z -3.91
F-Score4
WACC8.49%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.07%
EPS Next Y17.6%
EPS Next 2Y-31.23%
EPS Next 3Y-17.38%
EPS Next 5Y-15.45%
Revenue 1Y (TTM)139.55%
Revenue growth 3Y3.09%
Revenue growth 5Y-37.51%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y210.58%
EBIT growth 1Y21.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.54%
EBIT Next 3Y25.86%
EBIT Next 5Y-28.86%
FCF growth 1Y51.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.13%
OCF growth 3YN/A
OCF growth 5YN/A

BERGENBIO ASA / BGBIO.OL FAQ

What is the fundamental rating for BGBIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to BGBIO.OL.


Can you provide the valuation status for BERGENBIO ASA?

ChartMill assigns a valuation rating of 0 / 10 to BERGENBIO ASA (BGBIO.OL). This can be considered as Overvalued.


Can you provide the profitability details for BERGENBIO ASA?

BERGENBIO ASA (BGBIO.OL) has a profitability rating of 0 / 10.